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GRAPHICAL ABSTRACT 
 
HIGHLIGHTS 
 4-Phenylpyridine is a poor substrate for nicotinamide N-methyltransferase 
 4-Phenylpyridine metabolism demonstrates substrate inhibition kinetics 
 This arises due to docking in the active site in both an inhibitory and catalytic 
orientation 
 4-phenylpyridine metabolism is subject to competitive inhibition by 
dimethylsulphoxide 
 Nicotinamide N-methyltransferase does not increase 4-phenylpyridine toxicity in vitro 
 
Abstract 
The N-methylation of 4-phenylpyridine produces the neurotoxin 1-methyl-4-
phenylpyridinium ion (MPP+). We investigated the kinetics of 4-phenylpyridine N-
methylation by nicotinamide N-methyltransferase (NNMT) and its effect upon 4-
phenylpyridine toxicity in vitro. Human recombinant NNMT possessed 4-phenylpyridine N-
methyltransferase activity, with a specific activity of 1.7 ± 0.03 nmol MPP+ produced/h/mg 
NNMT. Although the Km for 4-phenylpyridine was similar to that reported for nicotinamide, 
its kcat of 9.3 x 10-5 ± 2 x 10-5 s-1 and specificity constant, kcat/Km, of 0.8 ± 0.8 s-1 M-1 were 
less than 0.15% of the respective values for nicotinamide, demonstrating that 4-
phenylpyridine is a poor substrate for NNMT. At low (<2.5 mM) substrate concentration, 4-
phenylpyridine N-methylation was competitively inhibited by dimethylsulphoxide, with a Ki 
of 34 ± 8 mM. At high (>2.5 mM) substrate concentration, enzyme activity followed 
substrate inhibition kinetics, with a Ki of 4 ± 1 mM. In silico molecular docking suggested 
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that 4-phenylpyridine binds to the active site of NNMT in two non-redundant poses, one a 
substrate binding mode and the other an inhibitory mode. Finally, the expression of NNMT in 
the SH-SY5Y cell-line had no effect cell death, viability, ATP content or mitochondrial 
membrane potential. These data demonstrate that 4-phenylpyridine N-methylation by NNMT 
is unlikely to serve as a source of MPP+. The possibility for competitive inhibition by 
dimethylsulphoxide should be considered in NNMT-based drug discovery studies. The 
potential for 4-phenylpyridine to bind to the active site in two binding orientations using the 
same active site residues is a novel mechanism of substrate inhibition.   
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1. INTRODUCTION 
Nicotinamide N-methyltransferase (NNMT, E.C. 2.1.1.1) N-methylates nicotinamide to 
produce 1-methylnicotinamide using S-adenosylmethionine as cofactor (Aksoy et al., 1994). 
NNMT is a cytosolic enzyme of approximately 29 kDa which is expressed in a variety of 
tissues, with highest level of expression in the liver (Parsons et al., 2002). NNMT expression 
in the healthy population follows a bimodal distribution, with 25% of subjects within each of 
low and high expressor categories (Smith et al., 1998; Parsons et al., 2002, 2003). NNMT has 
central roles in cellular energy homeostasis, signalling, survival and morphology (Parsons et 
al., 2011; Williams et al., 2013; Thomas et al., 2013), and in the human naïve embryonic 
stem cell it has been proposed as one of the main controllers of the epigenetic landscape 
(Sperber et al., 2015). The enzyme also has been proposed as a therapeutic target for the 
treatment of many diseases such as cancers (Kim et al., 2009; Emanuelli et al., 2010; Jung et 
al., 2017).  
 
Early studies upon the substrate specificity of porcine NNMT revealed a number of non-
physiological substrates, comprising close structural analogues of nicotinamide, for example 
thionicotinamide and 3-acetylpyridine (Alston and Abeles, 1988). These studies have been 
extensively cited in the literature to justify the identification of NNMT as responsible for the 
N-methylation of a range of pyridine-containing compounds such as quinolines and β-
carbolines (Parsons et al., 2002, 2003; Williams and Ramsden, 2005). Our recent studies have 
shown that the majority of these are poor NNMT substrates, with only isoquinoline 
demonstrating a catalytic efficiency (kcat/Km) value greater than 30% of that observed for 
nicotinamide (van Haren et al., 2016; Thomas et al., 2016).  
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The potential N-methylation of these endogenously-available compounds by NNMT is of 
interest as their N-methylated derivatives share close structural similarity to the potent 
Complex I inhibitor and dopaminergic neurotoxin 1-methyl-4-phenylpyridinium ion (MPP+) 
(Parsons et al., 2002, 2003; van Haren et al., 2016; Thomas et al., 2016). We have shown that 
NNMT is expressed in the dopaminergic neurones of the substantia nigra, which are 
destroyed in Parkinson’s disease (PD) (Parsons et al., 2002). Significantly, the enzyme is 
overexpressed in the cerebellum and caudate nucleus of brains of patients who have died of 
PD (Parsons et al., 2002, 2003). Thus it has been suggested that N-methylation may 
contribute to PD pathogenesis (Gearhart et al., 2000; Matsubara et al., 2002; Parsons et al., 
2002, 2003; Williams and Ramsden, 2005).   
 
4-Phenylpyridine (4-PP) is of interest because its N-methylated derivative is MPP+. 4-PP is 
an exogenously-derived compound found in, amongst others, oranges (Thomas and Bassols, 
1992) and mint (Snyder and D’Amato, 1985). 4-PP N-methylation by NNMT provides a 
direct metabolic pathway for the endogenous production of MPP+ (Figure 1). Due to its small 
size (155 Da) and hydrophobic nature (predicted logP = 2.6), 4-PP is likely to cross the blood 
brain barrier. Once inside the brain, its N-methylation by NNMT may lead to the 
accumulation of MPP+ and thus contribute to toxicity.  
 
We have previously reported that 4-PP is a substrate of NNMT, although its kinetics and its 
effect upon toxicity in vitro were not investigated (van Haren et al., 2016). Hence, in this 
study, we have (1) investigated the kinetics of 4-PP N-methylation using recombinant human 
NNMT (hNNMT), and (2) investigated the effect of NNMT expression upon 4-PP toxicity in 
vitro.  
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2. MATERIALS AND METHODS 
2.1. Materials 
Unless otherwise stated, all reagents were purchased from Sigma-Aldrich (Poole, UK) and 
were of the highest grade available. Cell culture reagents were purchased from Life 
Technologies (Paisley, UK). 4-PP was purified of contaminating MPP+ using preparative 
HPLC. 
 
2.2. 4-Phenylpyridine N-methyltransferase enzyme assay 
The ability of NNMT to N-methylate 4-PP was assessed using our previously-described 
NNMT assay (van Haren et al., 2016). hNNMT prepared as previously described (Thomas et 
al., 2016) was incubated with 1 mM 4-PP prepared in dimethylsulphoxide (DMSO) (5% v/v 
final concentration, approximately 700 mM) for 32 min. Samples were taken immediately 
after the addition of 0.5 mM S-adenosylmethionine (100 µM final concentration) and 
subsequently at time points shown in Figure 2A. MPP+ content was calculated using a MPP+ 
standard curve and expressed as pmol MPP+ produced ± SD. Linearity of pmol MPP+ 
produced vs. time was determined by linear regression analysis using Prism v5.0 (GraphPad, 
San Diego, CA, USA). Specific activity was calculated and expressed as pmol MPP+ 
produced/h/mg hNNMT ± SD (n = 3).  
 
2.3. Kinetic analysis 
hNNMT was incubated as described in section 2.2 with 0 – 10 mM 4-PP. Samples were taken 
at time points as described above, and initial velocity was calculated and expressed as nmol 
MPP+ produced/h. Data were modelled initially using Michaelis-Menten non-linear 
regression analysis. Due to the presence of substrate inhibition, two further analyses were 
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performed as previously described (Patel et al., 2013): (1) non-linear regression analysis 
using the following substrate inhibition kinetics equations (Lin et al., 2001; Wu, 2011): 
 
𝑣 =
𝑉𝑚𝑎𝑥.[𝑠]
𝐾𝑚+[𝑆](1+
[𝑆]
𝐾𝑖
)
 (equation 1) 
 
v = 𝑉𝑚𝑎𝑥.
(
[𝑆]
𝐾𝑚
)+(
𝛽[𝑆]2
𝛼𝐾𝑚𝐾𝑖
)
1+
[𝑆]
𝐾𝑚
+
[𝑆]
𝐾𝑖
+
[𝑆]2
𝛼𝐾𝑚𝐾𝑖
   (equation 2) 
 
and (2) Michaelis-Menten non-linear regression analysis of data from 0 – 1 mM 4-PP, i.e. 
prior to the onset of substrate inhibition at high substrate concentrations and thus 
representative of kinetics if NNMT were not to undergo substrate inhibition; such an 
approach has been used by ourselves and others (Lin et al., 2001; Patel et al., 2013; Bomati 
and Noel, 2005; Han et al., 2017). The kinetic constants Km, kcat and Ki were calculated for 
each modelling paradigm and expressed as µM ± SD and s-1 ± SD respectively (n = 3 for 
both). Km and kcat were used to calculate kcat/Km, which was expressed as s-1 M-1 ± SD (n = 3). 
 
2.4. Effect of DMSO concentration upon 4-phenylpyridine N-methylation  
Kinetic analysis of 4-PP N-methylation was performed as described in section 2.2, with 4-PP 
prepared in 1%, 3% and 5% DMSO (v/v final concentrations in reaction samples, 
approximately 140, 420 and 700 mM respectively). Data were calculated and expressed as 
nmol 4-PP produced/h ± SD (n = 3) and subjected to various analyses as described in section 
3.2. 
 
2.5. Molecular docking of 4-phenylpyridine to the active site of NNMT 
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Docking of 4-PP into the active site of human NNMT was performed using the Molegro 
Virtual Docker software (Thomsen and Christensen, 2006), the 2.72 Å resolution X-ray 
crystal structure of the NNMT enzyme complexed with S-adenosyl homocysteine and 
nicotinamide (Protein Databank entry, 3ROD (Peng et al., 2011), downloaded from the PDBe 
website http://www.ebi.ac.uk/pdbe (Berman et al., 2016; Young et al., 2017), and a 3D model 
of 4-PP downloaded from the NCBI Pubchem website (https://pubchem.ncbi.nlm.nih.gov/ 
(Kim et al., 2016)). The docking of the 4-PP ligand was confined within an 8 Å radius sphere 
centred on the known nicotinamide binding site, and with the S-adenosyl homocysteine 
retained in its bound position. Following a rigid body docking of the 4-PP, the conformation 
and position of the ligand were optimised to establish and/or improve hydrogen bonding to 
the protein. 
 
2.6. Cell culture 
SH-SY5Y human neuroblastoma cells (which have no endogenous NNMT expression) and 
S.NNMT.LP cells (comprising SH-SY5Y stably expressing a recombinant NNMT C-
terminally fused with the V5 epitope) were cultured as previously described (Parsons et al.,  
2011; Thomas et al., 2013, 2016). NNMT protein and mRNA expression were confirmed 
using Western blotting and RT-PCR respectively (Parsons et al., 2011) (data not shown).  
 
2.7. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reduction assay 
Cells were seeded at a density of 15,000 cells/well into the wells of a 96-well plate (Thermo 
Scientific, Loughborough, UK) in quadruplicate and incubated with 4-PP (12.5 – 1600 µM) 
for 48 and 120 h. As a positive control, cells were incubated with 500 µM 2N-
methylnorharman (MeNH). Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay as previously described (Thomas 
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et al., 2015). Results were calculated and expressed as percentage cell viability compared 
with that of untreated cells ± SD (n = 3 for 48 h, n = 5 for 120 h). Concentration was log-
transformed and subsequently data were modelled using non-linear regression analysis using 
the following equation: 
 
y = 𝑚𝑖𝑛𝑖𝑚𝑢𝑚 +  
𝑚𝑎𝑥𝑖𝑚𝑢𝑚−𝑚𝑖𝑛𝑖𝑚𝑢𝑚
1+10(𝐿𝑜𝑔𝐸𝐶50−𝑥)∗ℎ𝑖𝑙𝑙𝑠𝑙𝑜𝑝𝑒
  (equation 3) 
 
with a constraint of y = 0 for the minimum. From this, logEC50 was calculated for each 
replicate from which an average logEC50 ± SD (n = 3 for 48 h, n = 5 for 120 h) was 
calculated. To aid comprehension, this logEC50 value was antilogged to obtain EC50, which 
was expressed as µM; SD values were not antilogged due to the asymmetry obtained when 
the antilog of a logSD is obtained (Hancock et al., 1988).  
 
2.8. Lactate dehydrogenase cell death assay 
Cells were seeded and incubated with 4-PP as outlined in section 2.7 for 120 h, after which 
cell death was measured using the Pierce LDH Cytotoxicity Assay Kit (Thermo Fisher 
Scientific, Paisley, UK) as previously described (Thomas et al., 2015). Results were 
calculated, expressed and modelled using non-linear regression as described in section 2.7, 
with a constraint of y = 0 for the maximum (n = 4). 
 
2.9. Cellular ATP content assay 
Cells were seeded as described in section 2.7 into the wells of a poly-L-lysine-coated white 
96-well plate (Greiner Bio-One Ltd., Stonehouse, UK) and incubated with 4-PP as described 
in section 2.7 for 120 h. ATP content was measured as previously described (Thomas et al., 
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2016) and expressed as percentage cellular ATP content compared with that of untreated cells 
± SD (n = 5). Non-linear regression analysis was performed as described in section 2.7. 
 
2.10. Mitochondrial membrane potential 
Cells were seeded as described in section 2.7 into the wells of a poly-L-lysine-coated black 
96-well plate (Thermo Scientific, Loughborough, UK) and incubated with MPP+ as 
described in section 2.7 for 120 h. Membrane mitochondrial potential (MMP) was measured 
using the JC-1 mitochondrial membrane potential assay kit (Cayman Chemical Company, 
Michigan, USA) as previously described (Parsons et al., 2011) and expressed as percentage 
observed in untreated cells ± SD (n = 4). Non-linear regression analysis was performed as 
described in section 2.7. 
 
2.11. Statistical Analysis. 
All analyses were undertaken using Prism v5.0. In all instances, P < 0.05 was taken to 
indicate statistical significance. Statistical analysis of cell viability, cell death, cellular ATP 
content and MMP was performed as previously described (Thomas et al., 2016). Briefly, 
comparison of all four endpoint measures at each concentration with values observed in 
untreated cells was performed using one-way ANOVA with Tukey post-hoc comparisons, 
with concentration as independent variable (IV) and endpoint measure as dependent variable 
(DV). Comparison of toxicity between cell lines and time points for each concentration was 
performed using two-way ANOVA with Dunnett’s post-hoc comparisons, with cell line and 
4-PP or MeNH concentration as IV and endpoint measure as DV. Statistical comparison of 
EC50s obtained from the MTT reduction assay was performed using two-way ANOVA, with 
cell line and length of incubation as IVs and logEC50 as DV. Statistical comparison of cell 
death, cellular ATP content and MMP EC50 values were performed using Student’s t-test with 
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Welch correction, with cell line as IV and logEC50 as DV. Statistical comparisons were 
performed upon logEC50 values as they follow a normal distribution (Hancock et al., 1988). 
 
3. RESULTS 
3.1. NNMT demonstrated 4-phenylpyridine N-methyltransferase activity and substrate 
inhibition kinetics 
To determine whether NNMT was capable of N-methylating 4-PP, we incubated hNNMT 
with 1 mM 4-PP prepared in DMSO (5% v/v final concentration, approximately 700 mM) 
(Figure 2). MPP+ production increased linearly with time (Figure 2A), with a specific 
activity of 1.7 ± 0.03 nmol MPP+ produced/h/mg hNNMT.  
 
To estimate kinetic constants for 4-PP N-methylation, we incubated NNMT with 4-PP (0 – 10 
mM), and performed Michaelis-Menten non-linear regression analysis upon resulting initial 
velocities (Figure 2B). The results are summarised in Table 1. Comparison with values 
published for nicotinamide (van Haren et al., 2016) revealed that 4-PP is a poor substrate for 
NNMT. Michaelis-Menten analysis produced a Km similar to that we have previously 
reported for nicotinamide, whereas kcat and kcat/Km were only 0.1% and 0.15% of those for 
nicotinamide. Due to the poor goodness of fit obtained (R2 = 0.54), the data was subsequently 
modelled using non-linear substrate inhibition kinetics which, although provided significantly 
better goodness of fit (R2 = 0.96), returned ambiguous values for Vmax, Km and Ki (data not 
shown). Data was then modelled with a variety of substrate inhibition equations in order to 
obtain a best kinetic fit (Lin et al., 2001; Wu, 2011). Km was 12-fold higher than that reported 
for nicotinamide, with kcat and kcat/Km being 0.6% and 0.04% of the respective values. The ki 
for 4-PP substrate inhibition was similar to those reported for other NNMT substrates which 
demonstrated substrate inhibition, which were in the range 4.7 – 20.2 mM (van Haren et al., 
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2016). To estimate kinetic parameters for 4-PP N-methylation in the absence of substrate 
inhibition, data between 0 – 1 mM 4-PP, i.e. prior to the onset of substrate inhibition, were 
subjected to Michaelis-Menten analysis (R2 = 0.96). The resulting Km was 8-fold higher, and 
kcat and kcat/Km values were 0.4 and 0.04%, of values for nicotinamide.  
 
3.2. DMSO is a competitive inhibitor of 4-phenylpyridine N-methylation by NNMT 
As DMSO is reported to be a competitive inhibitor of a number of enzymes (Plummer et al., 
1983; Banasik et al., 2004; Kwak et al., 2009), we investigated whether DMSO was a 
competitive inhibitor of 4-PP N-methylation by NNMT (Figure 3). 
 
Specific activity decreased with increasing DMSO concentration (Figure 3A), resulting in 
specific activities of 2.6 ± 0.06, 1.8 ± 0.05 and 1.5 ± 0.1 nmol MPP+ produced/h/mg hNNMT 
at 1, 3 and 5% DMSO (v/v final concentration) respectively (P < 0.001). Non-linear substrate 
inhibition regression analysis of the data (Figure 3B) revealed that increasing DMSO 
concentration decreased velocity, v, at 4-PP concentrations below 2.5 mM, i.e. prior to the 
onset of substrate inhibition. As it is likely that physiological concentrations of 4-PP are 
below 2.5 mM, Michaelis-Menten kinetic modelling was performed using data truncated at 
2.5 mM (Figure 3C), from which apparent Km (Kmapp) and Vmax (Vmaxapp) values for each 
concentration of DMSO were calculated, which are summarised in Table 2. Vmaxapp values did 
not alter significantly whereas Kmapp values increased with increasing DMSO concentration, 
hence DMSO is a competitive inhibitor of 4-PP N-methylation. As a confirmatory exercise, 
the same data were modelled using an Eadie-Hofstee plot, v vs. v/[S] (Figure 3D), which 
confirmed the presence of competitive inhibition of 4-PP N-methylation by DMSO. The kcat 
and kcat/Km values for all concentrations of DMSO were calculated and are summarised in 
Table 2. As expected for a competitive inhibitor, kcat did not alter whereas kcat/Km decreased 
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with increasing DMSO concentration. Catalytic efficiency was significantly reduced by all 
three concentrations of DMSO, with an 82% reduction at 1% v/v DMSO. 
 
To estimate the Km of 4-PP in the absence of DMSO, Kmapp was plotted against DMSO 
concentration (Plummer et al., 1983) (Figure 3E), from which Km was calculated via 
extrapolation as 155 µM. The Ki for DMSO substrate inhibition was calculated by first 
calculating the inhibition factor, α, for each concentration of DMSO using the following 
equation: 
 
𝛼𝐾𝑚 = 𝐾𝑚𝑎𝑝𝑝 
 
Ki was then calculated using the following equation: 
 
𝛼 = 1 +
[DMSO]
𝐾𝑖
 
 
All three Ki values were then averaged to obtain a mean of 34 ± 8 mM.  
 
Km and Vmax values of 155 µM and 48 pmol MPP+ produced/h (Vmax being derived from the 
average of Vmaxapp for all three concentrations of DMSO) were then used to calculate the 
activity of 4-PP N-methylation in the absence of DMSO using Michaelis-Menten regression 
analysis (Figure 3C). Specific activity in the absence of DMSO was extrapolated from a plot 
of specific activity vs. DMSO concentration (Figure 3F), from which the specific activity was 
estimated to be 2.8 ± 0.2 nmol MPP+ produced/h/mg hNNMT.  
 
3.3. 4-Phenylpyridine docks to the hNNMT active site in two non-redundant orientations 
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Molecular docking was used to investigate the interaction of 4-PP with the NNMT active site. 
To confirm the accuracy of the docking protocol, initially hNNMT was docked with 
nicotinamide (Figure 4A). As expected (Peng et al., 2011), the pyridine ring of nicotinamide 
formed an electrostatic interaction with Y20 and was also held within a hydrophobic clamp 
comprising Y204 and L164. The amide group of nicotinamide formed hydrogen bonds with 
S201, S213 and D197.  
 
A total of 50 docking trials for 4-PP were made, yielding just two non-redundant 4-PP poses 
(taking an RMSD ≤ 1 Å on atomic co-ordinates as the criterion of pose similarity), each of 
which was returned 25 times. The first pose presented 4-PP in a presumed substrate binding 
mode (Figure 4B), in which the 4-PP pyridine ring interacted with Y20, Y204 and L164 as 
described for nicotinamide. However, due to the lack of an amide group, there were no 
hydrogen bonding interactions between 4-PP and S201, S213 and D197. There were no 
interactions between the aromatic phenyl ring of 4-PP and the active site of hNNMT.  
 
In the second pose, 4-PP was orientated almost 180o with respect to the first pose (Figure 
4C). This second pose most likely represents an inhibitory binding mode due to the lack of 
proximity between the pyridine nitrogen and the catalytically essential Y20 (Peng et al., 
2011). The phenyl ring formed a hydrophobic interaction with L164 and pi-pi stacking with 
Y204. The pyridine nitrogen of 4-PP is orientated in a similar position to the amide nitrogen 
of nicotinamide, hence forming hydrogen bond interactions with S201 and S213, but not 
D197.   
 
Docking studies were also performed using isoquinoline (Figure 5), a substrate of NNMT 
which also demonstrates substrate inhibition (van Haren et al., 2016). As observed with 4-PP, 
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a total of 50 docking trials yielded just two non-redundant poses, each of which was returned 
25 times. The first pose presented isoquinoline in a presumed substrate binding mode (Figure 
5A) and the second a presumed inhibitory binding mode (Figure 5B), as determined by the 
relative proximity of the pyridine nitrogen to Y20. Each pose used the same active site 
residue interactions with the phenyl and pyridine rings as observed for 4-PP. 
 
3.4. Neither NNMT expression nor length of incubation influenced 4-phenylpyridine 
toxicity in vitro 
The MTT reduction cell viability assay, an early-stage measure of toxicity (Thomas et al., 
2015), was used to determine whether NNMT increased 4-PP toxicity in vitro after 48 and 
120 h incubation (Figure 6 and Tables 3 & 4). 4-PP was toxic towards both SH-SY5Y and 
S.NNMT.LP cells at concentrations of 400, 800 and 1600 µM at both time points (Table 3). 
The length of incubation had no effect upon 4-PP toxicity at any of the concentrations 
investigated for either cell-line. There was no significant difference in logEC50 for each cell-
line at either time point (Table 4). As a positive control for the effect of NNMT expression 
upon toxicity, the effect of 0.5 mM MeNH, a compound whose in vitro toxicity we have 
shown to increase with length of incubation, was investigated. MeNH was significantly more 
toxic towards both SH-SY5Y and S.NNMT.LP cells after 120 h compared with 48 hr 
incubation (SH-SY5Y: 78.5 ± 3% vs. 10.7 ± 6.1%, P < 0.001, n = 3; S.NNMT.LP: 52.2 ± 
3.8% vs. 22.1 ± 18.4%, P < 0.01, n = 4). MeNH was significantly more toxic towards 
S.NNMT.LP compared to SH-SY5Y cells after 48 hr incubation (P < 0.05), although after 
120 h incubation there was no difference in toxicity. 
 
The LDH cytotoxicity assay, a late-stage measure of toxicity (Thomas et al., 2015), was used 
as an additional confirmatory toxicity assay (Figure 7A and Table 3). 4-PP was toxic towards 
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SH-SY5Y cells at 1600 and 800 µM, and towards S.NNMT.LP cells at 1600, 800 and 400 
µM. There was no significant difference in logEC50 values for each cell-line (-2.51 ± 0.3 vs. -
2.17 ± 0.1, equivalent to 3090 µM and 6761 µM respectively, P = 0.2). 
 
The low catalytic efficiency of 4-PP N-methylation by NNMT (Table 2) in tandem with the 
lack of effect of NNMT expression upon 4-PP toxicity in vitro suggested that the degree of 
intracellular 4-PP N-methylation by NNMT is insignificant. As a confirmatory exercise, we 
investigated the effect of NNMT expression after 120 hr incubation upon two parameters of 
mitochondrial function - cellular ATP content and MMP (Parsons et al., 2011). Our 
hypothesis was that increased 4-PP N-methylation by NNMT would result in increased 
MPP+ production and accumulation within the cell, the consequence of which would be 
Complex I inhibition, a decrease in the MMP (Figure 7B and Table 3) and a subsequent 
reduction in intracellular ATP content (Figure 7C and Table 3). The MMP of SH-SY5Y cells 
was significantly decreased at 200, 400, 800 and 1600 µM 4-PP, and in S.NNMT.LP cells at 
400, 800 and 1600 µM 4-PP. There was no significant difference in MMP between each cell-
line at any concentration of 4-PP investigated. There was no significant difference in logEC50 
for each cell-line (-2.69 ± 0.32 vs. -2.17 ± 0.14, equivalent to 2023 vs. 2280 µM, P = 0.5).  
 
Intracellular ATP content of SH-SY5Y cells was significantly decreased at 800 and 1600 µM 
4-PP, yet was increased at 100, 200 and 400 µM. In S.NNMT.LP cells, 4-PP decreased 
intracellular ATP content at concentrations of 800 and 1600 µM, with no concentration 
increasing intracellular ATP concentration. Intracellular ATP content was significantly higher 
in SH-SY5Y cells compared with that of S.NNMT.LP cells at 200 (157.6 ± 19.7% vs. 109.8 ± 
34.4%, P < 0.01) and 400 µM (135.2 ± 23% vs. 95.2 ± 25.9%, P < 0.05) 4-PP. There was no 
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significant difference in logEC50 values for each cell-line (-3.13 ± 0.04 vs. -3.2 ± 0.07, 
equivalent to 738 vs. 625 µM, P = 0.12).  
 
4. DISCUSSION 
4.1. 4-PP is a substrate of NNMT 
Our kinetic analysis of 4-PP N-methylation by hNNMT demonstrated that 4-PP was rather a 
poor substrate, even when the inhibitory effect of DMSO was taken into account. 4-PP is an 
exogenous compound whose abundance in the diet is very low. Its content in Brassica 
campestris L. ssp. Pekinensis, for example, is as little as 0.9% (Hong and Kim, 2013). Hence, 
even for someone eating an exclusively vegetarian diet it is unlikely that the concentration of 
4-PP within the brain will be sufficiently high to outcompete nicotinamide as a substrate for 
NNMT. Even if it were to reach such a concentration, the low rate of catalytic turnover would 
more likely result in the inhibition of nicotinamide N-methylation. Hence, it is unlikely that 
NNMT-mediated 4-PP metabolism is a source of MPP+. This is supported by the failure of 
NNMT expression to increase the toxicity of 4-PP due to increased MPP+ production in 
S.NNMT.LP cells, even at concentrations which were significantly higher than what would 
be expected physiologically. As MPP+ is actively sequestered into mitochondria due to its 
positive charge (Trevor et al., 1987), it could be argued that, with even such a low catalytic 
turnover, over a much longer period of time the slow but continuous N-methylation of 4-PP 
may result in a toxic accumulation of MPP+ within the mitochondria, resulting in Complex I 
inhibition and depletion of the MMP, and ultimately cell death. It is also possible that mature 
neurones, which rely predominantly upon mitochondrially-derived ATP (Zheng et al., 2016), 
may be more susceptible to long-term MPP+ accumulation, compared to tumour cells in 
culture which rely predominantly upon glycolysis (Vander Heiden et al., 2009). In vivo 
studies using acute high-dose 4-PP administration have failed to support this (Bradbury et al., 
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1985; Perry et al., 1987; Irwin et al., 1987; Godin and Crooks, 1989; Carr and Basham, 1991) 
and to date no study using NNMT-overexpressing in vivo models have reported such 
observations.  
 
4.2. 4-PP N-methylation by NNMT displayed substrate inhibition kinetics 
Although 4-PP is a minor substrate of NNMT, its kinetics are of interest as they reveal that 
NNMT-mediated 4-PP N-methylation was subject to both substrate and competitive 
inhibition. Below concentrations of 2.5 mM 4-PP, competitive inhibition by DMSO was 
observed, whereas at concentrations higher than 2.5 mM, substrate inhibition occurred. This 
has important consequences for NNMT-based drug discovery studies, as it is a therapeutic 
target for a number of diseases, in particular cancer. 
 
Molecular docking revealed that 4-PP is able to dock with the NNMT active site in two non-
redundant poses, one of which we propose is a substrate binding mode and the other an 
inhibitory binding mode as deduced by the proximity of the pyridine nitrogen to Y20. The 
substrate inhibition can thus be rationalised to arise due to competition between these two 
binding modes. In its inhibitory binding mode, 4-PP interacts with the active site via both its 
phenyl and pyridine rings, whereas in its substrate binding mode it interacts only via its 
pyridine ring, with the increased number of interactions presumably favouring the inhibitory 
binding mode at high 4-PP concentration.  
 
Mechanistically, this is of interest, as it represents a previously unreported mechanism of 
substrate inhibition. To date, two mechanistic models have been proposed. The first model 
involves the formation of a ternary dead-end complex comprising the substrate interacting 
with the end-product of cofactor metabolism within the active site at high substrate 
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concentrations (Wu, 2011; Tyapochkin et al., 2009). The second model predicts the presence 
of two substrate binding sites, the first a catalytically-active high affinity site and the second a 
catalytically-inactive low affinity site, either within or separate to the active site itself (Lin et 
al., 2001; Wu, 2011). At high substrate concentration, binding to the catalytically-inactive 
site prevents the binding of substrate to the catalytically-active site either via direct steric 
hindrance, as for example warfarin binding within the active site of cytochrome P450 2C9 
(Williams et al., 2003), or the induction of a conformational change of the protein, as for 
example dehydroepiandrosterone binding to sulphotransferase 2A1 (Tracy and Hummel, 
2004; Allali-Hassani et al., 2007). Our molecular docking study suggests a novel mechanism 
in which 4-PP binds to the active site of NNMT in two orientations, one a catalytic and the 
other a non-catalytic orientation, both of which bind to a single binding site using the same 
amino residue interactions. The ability to bind in this manner arises due to 4-PP possessing 2-
fold rotational symmetry. In support of this, the majority of NNMT substrates which 
demonstrate substrate inhibition are quinoline and its analogues, compounds which also 
demonstrate two-fold rotational symmetry (Figure 8) and have Ki values similar to that of 4-
PP (van Haren et al., 2016). Molecular docking of isoquinoline returned the same binding 
poses and active site amino acid residue interactions as 4-PP, and has a Ki of 20 mM which is 
similar to that for 4-PP. 
 
4.3. 4-PP N-methylation undergoes competitive inhibition by DMSO 
Our results demonstrate that DMSO is a competitive inhibitor of 4-PP N-methylation by 
NNMT. Many studies of enzyme kinetic reactions utilise DMSO as a solvent for solubilising 
non-polar substrates (van Haren et al.,  2016; Faulds et al., 2011; Patel et al., 2013), usually at 
concentrations below 5% (approximately 700 mM). We have shown that preparing 
nicotinamide in 5% DMSO results in more reliable estimation of the kinetic parameters of 
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nicotinamide N-methylation compared to nicotinamide prepared in phosphate-buffered saline, 
which we ascribed to the relative insolubility of nicotinamide in phosphate-buffered saline 
compared to DMSO which resulted in less nicotinamide delivered to the assay (Patel et al.,  
2013). Although DMSO has no effect upon the activity of a number of enzymes (Chauret et 
al., 1998; Tsitanou et al., 1999; Easterbrook et al., 2001), DMSO is known to be a 
competitive inhibitor of many enzymes (Perlman and Wolff, 1968; Plummer et al., 1983; 
Chauret et al., 1998; Banasik and Ueda, 1999; Easterbrook et al., 2001; Banasik et al., 2004). 
We were unable to determine, using molecular docking, how DMSO binds to the NNMT 
active site. This was due to the small size of the molecule and the vast number of potential 
interactions within the large active site of NNMT. Where crystal structures of DMSO 
complexed with other enzymes have been obtained, in many instances DMSO interacts with 
inorganic metal ions within their active sites. For example, the crystal structure of P450 BM-
3 reveals that the sulphur atom of DMSO interacts with the iron of the heme group (Kuper et 
al., 2007). DMSO can also interact directly with amino acid residues. For example, the 
inhibition of liver alcohol dehydrogenase involves co-ordination with amino acid residue S48 
as well as the metal ion within the active site (Meijers et al., 2007). As NNMT does not 
require an active site metal ion for activity, it can be assumed that DMSO interacts directly 
with residues within the active site.  
 
The limited numbers of studies which have calculated a Ki for DMSO reveal it to be a poor 
inhibitor, with values ranging from 5 mM for alcohol dehydrogenase (Perlman and Wolff, 
1968) to 70 mM for acetylcholinesterase (Plummer et al., 1983). The Ki for NNMT N-
methylation of 4-PP is in accord with these values. Although not a potent inhibitor, the 
concentrations of DMSO routinely used in enzyme reactions are significantly above these Ki 
values, being approximately 20-fold higher for 4-PP N-methylation by NNMT. Therefore it is 
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likely that many studies are performed using sub-optimal enzyme activity, and are thus 
reporting incorrect Km and kcat/Km values, as evidenced in our study. Hence, the use of 
alternative solvents for kinetic studies such as acetonitrile and methanol should be 
considered. Studies of cytochrome P450s, UDP glucuronosyltransferases and 
phenolsulphotransferases show that concentrations of up to 1% methanol and 2% acetonitrile 
had little effect upon their activities, in contrast to DMSO (Chauret et al., 1998; Easterbrook 
et al., 2001). However, these solvents can also act as enzyme inhibitors (Busby et al., 1999), 
so care must be taken to assess the effect of solvents upon enzyme catalytic activity in order 
to choose the most appropriate. 
 
This is of particular importance for the screening of compounds in drug discovery studies in 
which the therapeutic target is NNMT. It is possible that, in addition to acting as a 
competitive inhibitor of substrate metabolism, DMSO may also compete with competitive 
inhibitors for the active site, thus reducing their efficacy. For example, DMSO binds to the 
same binding site in the active site of lysozyme as its inhibitor N-acetylglucosamine, reducing 
its inhibitory efficacy (Johannesson et al., 1997). Also, increasing concentrations of DMSO 
increased the IC50 values of all lipophilic and hydrophilic inhibitors of poly(ADP-ribose) 
synthetase investigated by upto 10-fold, with the IC50 of 6(5H)-phenanthridinone increasing 
33-fold (Banasik and Ueda, 1999). Thus, the use of DMSO in enzyme assays can potentially 
affect candidate inhibitor efficacy sufficiently to lead to their unwarranted removal from drug 
inhibitor screens. The small size of DMSO makes its docking to protein active sites 
somewhat complicated to predict, in particular for enzymes such as NNMT which have large 
active sites, thus it is very difficult to predict whether DMSO may interfere with candidate 
inhibitor docking and thus inhibitory activity. However, by using the kinetic approaches used 
in this study, it will be possible to determine whether DMSO is an appropriate solvent for 
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inhibitor screening, thus reducing the likelihood of removing candidate inhibitors due to 
incorrect determination of IC50 and Ki. 
 
5. CONCLUSIONS: these findings suggest that the N-methylation of 4-PP into the 
dopaminergic neurotoxin MPP+ is unlikely to occur within the cell and is thus unlikely to 
contribute to the pathogenic process of PD.   
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FIGURE LEGENDS 
Figure 1. Biosynthetic routes for 1-methyl-4-phenylpyridinium ion. MPP+ is produced 
within the brain via the monoamine oxidase B-mediated oxidation of MPTP. An alternative 
route of production has been proposed to occur via the NNMT-mediated N-methylation of 4-
PP.   
 
Figure 2. Kinetic analysis of 4-phenylpyridine N-methylation by NNMT. (A) Linearity of 
MPP+ production with time. Results are expressed as pmol MPP+ produced ± SD (n = 3). 
(B) Non-linear regression analysis of 4-PP N-methylation using various kinetic models to 
obtain values for Vmax, Km and Ki. Results are expressed as pmol MPP+ produced/h ± SD (n = 
3). a = Michaelis-Menten kinetics; b = substrate inhibition kinetics using equation 2; c = 
Michaelis-Menten kinetics of data truncated at 1 mM 4-PP.  
 
Figure 3. Analysis of the effect of dimethylsulphoxide upon 4-phenylpyridine N-
methylation kinetics. (A) Effect of increasing DMSO concentration upon linearity of MPP+ 
production with time. (B) Non-linear substrate inhibition kinetic regression analysis of the 
effect of increasing DMSO concentration upon MPP+ production. (C) Michaelis-Menten 
kinetic modelling of data truncated at 2.5 mM 4-PP, which was subsequently used to obtain 
Km and Vmax values for each concentration of DMSO. For comparison, kinetic analysis of 
enzyme activity in the absence of DMSO, predicted using Vmax and Km values calculated from 
data presented in this and panel E, is also shown. (D) Eadie-Hofstee plot of data truncated at 
2.5 mM 4-PP, confirming the presence of competitive inhibition of 4-PP N-methylation by 
DMSO. (E) Effect of DMSO concentration upon apparent Km, calculated using data 
presented in panel C, from which an estimate for Km in the absence of DMSO was obtained 
via extrapolation. (F) Effect of DMSO concentration upon specific activity, from which an 
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estimate for specific activity in the absence of DMSO was obtained via extrapolation. For 
panels A – D: ● = 1% DMSO; ■ = 3% DMSO; ▲ = 5% DMSO. For panel D only:  = 
predicted activity in the absence of DMSO. All concentrations of DMSO are v/v. 
 
Figure 4. In silico molecular docking of nicotinamide and 4-phenylpyridine to the active 
site of NNMT. (A) Nicotinamide. (B) 4-PP in a predicted substrate binding orientation. (C) 
4-PP in a predicted inhibitor binding orientation. 
 
Figure 5. In silico molecular docking of isoquinoline to the active site of NNMT. (A) 
Isoquinoline in a predicted substrate binding orientation. (B) Isoquinoline in a predicted 
inhibitor binding orientation. 
 
Figure 6. Effect of NNMT expression upon 4-phenylpyridine toxicity in vitro using the 
MTT reduction cell viability assay. Cell viability is expressed as percentage of untreated 
cells ± SD (n = 3 for 48 h incubation, n = 5 for 120 h incubation). Statistical analysis 
comprised (i) toxicity of each concentration vs untreated cells using one-way ANOVA 
(results are summarised in Table 3) and (ii) toxicity between cell-lines at each individual 
concentration using two-way ANOVA (results shown on graph; all comparisons were P > 
0.05). EC50 values shown are derived from logEC50 ± SD values. (A) 48 h incubation. (B) 
120 h incubation. For both panels: ● = SH-SY5Y; ▲ = S.NNMT.LP. 
 
Figure 7. Effect of NNMT expression upon 4-phenylpyridine toxicity in vitro using the 
LDH cytotoxicity assay, MPP analysis and cellular ATP content assay. (A) Cell death is 
expressed as percentage observed in untreated cells ± SD (n = 4). (B) MMP is expressed as 
percentage observed in untreated cells ± SD (n = 4). (C) Cellular ATP content is expressed as 
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percentage observed in untreated cells ± SD (n = 5).  For all panels, statistical analysis 
comprised (i) toxicity of each concentration vs untreated cells using one-way ANOVA 
(results are summarised in Table 3) and (ii) toxicity between cell-lines at each individual 
concentration using two-way ANOVA (results shown on graph): * = P < 0.05; ** = P < 0.01. 
● = SH-SY5Y; ▲ = S.NNMT.LP. 
 
Figure 8. Structural similarity between 4-phenylpyridine and quinolone analogues 
whose N-methylation by NNMT demonstrate substrate inhibition kinetics. 
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TABLES 
 
TABLE 1. Calculated Km, Ki, kcat and kcat/Km values for NNMT 4-phenylpyridine N-
methyltransferase activity. Values are expressed ± SD. 
 
Non-linear regression analysis 
  
Km 
(µM) 
Ki 
(µM) 
kcat x 10-4 
(s-1) 
Kcat/Km 
(s-1 M-1) 
Michaelis-Menten 125 ± 111 - 0.93 ± 0.2 0.8 ± 0.8 
Substrate inhibitiona 2375 ± 187 4011 ± 963 5.7 ± 0.3 0.2 ± 0.03 
Truncated Michaelis-Mentenb 1511 ± 348 - 3.6 ± 0.5 0.2 ± 0.09 
Nicotinamidec 199 ± 32 - 1000 510 
 
aCalculated using equation 2 outlined in section 2.2. 
bData was truncated to include only 0 – 1 mM 4-PP. 
cData previously calculated for nicotinamide shown for comparison purposes. 
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TABLE 2. Calculated values of Kmapp, kcat and kcat/Km for dimethylsulphoxide 
competitive inhibition. 
 
DMSO 
(% v/v) 
Vmaxapp 
(pmols 
MPP+/h) 
Kmapp  
(µM) 
kcat x 10-4  
(s-1) 
kcat/Km 
(s-1 M-1) 
Catalytic 
efficiency 
(percentage)a 
0b 48.1 155 2.8 1.7 100 
1 51 939 2.8 0.3 18 
3 44 1869 2.5 0.1 6 
5 49 3565 2.8 0.08 5 
 
aCatalytic efficiency expressed as percentage of kcat/Km at 0% DMSO. 
bPredicted values, calculated as described in section 3.2. 
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TABLE 3. Summary of significant changes in cell viability (MTT) and intracellular 
ATP concentrations (ATP) in SH-SY5Y and S.NNMT.LP cells. For MTT experiments, 
results are expressed as percentage viability compared to untreated cells ± SD (n = 3 for 48 h 
incubation, n = 5 hr for 120 h incubation). For LDH experiments, results are expressed as cell 
death compared to untreated cells ± SD (n = 4). For MMP experiments, results are expressed 
as percentage observed in untreated cells ± SD (n = 4). For ATP experiments, results are 
expressed as percentage observed in untreated cells ± SD (n = 5). Statistical analysis 
comprised comparison of cellular response at each 4-PP concentration compared to untreated 
cells using one-way ANOVA.  
 Concentration (µM)a 
100 200 400 800 1600 
MTT 48 h SH-SY5Y - - 44.3b   ± 
10.7 
22.4 ± 0.7 0.8 ± 1.2 
 S.NNMT.LP - - 51.8   ± 
12.5 
13.5 ± 2.9 0.5 ± 0.3 
MTT 120 h SH-SY5Y - - 46.5 ± 
28.8 
0.7   ± 1.8 -0.9 ± 0.2 
 S.NNMT.LP - - 37.2 ± 
22.6 
0.2   ± 1.3 -1 ± 0.4 
LDH SH-SY5Y - - - 22.6 ± 6.7 26.9 ± 5 
 S.NNMT.LP - - 9.4 ± 
3.6** 
22 ± 5.2 25 ± 2.3 
MMP SH-SY5Y - 83.5 ± 
8.1** 
79.3 ± 3.5 70.6 ± 4.6 53.9 ± 
1.07 
 S.NNMT.LP - - 68.7 ± 
10.9 
65.1 ± 
10.9 
52.9 ± 7.1 
ATPc SH-SY5Y 137.4 ± 157.6 ± 135.2 ± 37.8 ± -1.3 ±   
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18.8* 19.7** 23* 15.4** 5.1 
 S.NNMT.LP - - - 24.4 ± 
11.4 
-3.1 ± 8.7 
 
aConcentrations below 100 µM elicited no significant changes in any of the endpoints 
measured and are thus not included. The exception to this was a significant decrease in SH-
SY5Y cell death at 25 µM 4-PP (P < 0.05). 
bOnly statistically significant results are shown and are P < 0.001 unless otherwise indicated: 
* = P < 0.05, ** = P < 0.01.  
cATP content in untreated cells: SH-SY5Y = 178 ± 68 pmol/mg protein; S.NNMT.LP = 337 
± 65 pmol/mg protein. 
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TABLE 4. Summary of logEC50 ± SD and their corresponding antilog values for the 
MTT assay. LogEC50 values are log Molar concentrations. The antilogs of the EC50 values 
are shown in brackets and are expressed as µM; the antilog of the SD is not shown due to the 
resulting asymmetry generated. Values are the average of three (48 h) or five (120 h) 
experiments. Statistical analysis was performed upon the logEC50 ± SD values using two-way 
ANOVA. All comparisons were P > 0.05. 
 48 h 120 h 
SH-SY5Y -3.43 ± 0.05 (372) -3.41 ± 0.07 (391) 
S.NNMT.LP -3.38 ± 0.05 (416) -3.46 ± 0.07 (344) 
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